The appointment marks the ongoing transition of Patrys to a clinical development company and recognises that as an active member of the Board, Dr. Roskrow will be able to participate more fully in the planning of the direction and future strategy of the Company.
Dr. Roskrow joined the Company in the role of Chief Medical Officer and President in August 2010 and was appointed as Chief Executive Officer effective July 2011. Since joining Patrys she has been directing the Company’s clinical development and working closely with the Board and management team on corporate strategy and global business development.
Dr. Roskrow has an extensive network of relationships with key public and private biotechnology and pharmaceutical companies and leading clinical centres in the USA, Europe and Asia. Patrys benefits from these relationships and her significant healthcare investment banking experience.
Dr. Roskrow earned with Honours a medical degree (Medicine and Surgery) and a PhD (Medicine) from the University of London. She has held many high level clinical and research positions, most recently at the Institute for Molecular Immunology, GSF, Munich, Germany. She has extensive experience related to the early and later-stage clinical development of promising new anti-cancer products and has published more than 30 original papers in quality peer-reviewed journals.
Dr. Roskrow was also a Senior Director of Investment Banking in the Healthcare Group at Lazard Ltd (USA and Australia) where she participated in mergers & acquisitions, company financings, product out-licensing deals, R&D collaborations and transactions.
She has served as an independent board member for two private biotechnology companies.
Patrys’ Chairman Mr. John Read said: “I am delighted that Marie has accepted this appointment to the role of Managing Director. This change comes at a time when the Company is making significant progress in the development of its clinical stage products PAT-SM6, PAT-LM1 and PAT-SC1. Marie’s investment banking experience will also be integral to a successful capital raising.
“This appointment marks the beginning of the review of the composition of the Board. We intend to further enhance the Board’s skill set once the capital raising has been completed. My fellow directors and I look forward to working closely with Marie as we continue to move Patrys forward."
